Akebia Therapeutics/$AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Primary listing
Employees
181
Headquarters
Website
AKBA Metrics
BasicAdvanced
$782M
-
-$0.16
0.96
-
Price and volume
Market cap
$782M
Beta
0.96
52-week high
$4.08
52-week low
$1.24
Average daily volume
4.2M
Financial strength
Current ratio
1.977
Quick ratio
1.77
Long term debt to equity
609.431
Total debt to equity
670.329
Interest coverage (TTM)
0.14%
Profitability
EBITDA (TTM)
23.359
Gross margin (TTM)
83.22%
Net profit margin (TTM)
-17.91%
Operating margin (TTM)
1.97%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
0.89%
Return on equity (TTM)
1,610.77%
Valuation
Price to revenue (TTM)
3.357
Price to book
26.55
Price to tangible book (TTM)
-26.02
Price to free cash flow (TTM)
-268.109
Free cash flow yield (TTM)
-0.37%
Free cash flow per share (TTM)
-0.011
Growth
Revenue change (TTM)
16.75%
Earnings per share change (TTM)
-21.58%
3-year revenue growth (CAGR)
-11.55%
3-year earnings per share growth (CAGR)
-44.00%
10-year earnings per share growth (CAGR)
-21.89%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
Bulls say / Bears say
The Vafseo launch had a solid start, posting $12.0 million in net product revenue in Q1 2025 and showing early demand for the anemia therapy (GlobeNewswire)
Auryxia produced $43.8 million in net product revenue in Q1 2025 even after losing exclusivity, supported by its inclusion in the TDAPA reimbursement bundle (GlobeNewswire)
A $50 million equity offering increased cash and equivalents to $113.4 million at the end of Q1 2025, supporting the path to profitability with the current operating plan (GlobeNewswire)
Auryxia lost U.S. exclusivity on March 20, 2025, making the product vulnerable to generic competition, which could reduce future phosphate binder revenues (GlobeNewswire)
Vafseo uptake is currently highest among small and mid-sized dialysis providers, with major organizations only starting to order, possibly delaying wider market adoption (GlobeNewswire)
The company posted $5.4 million in interest expense in Q1 2025 related to the Vifor settlement royalty liability, reflecting a substantial financing burden (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $782M as of September 14, 2025.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of September 14, 2025.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.